Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CAR T Cells G-Rex®24 Well Plate

Publication Date: March 28, 2023

Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells

An Is2 insulator placed in the 3′ long terminal repeat of an all-in-one, transactivator-free, doxycycline-responsive lentiviral vector (LOPIs2) gave tight control of transgene expression in primary human T cells, which the same vector without the insulator could not achieve. LOPIs2 T cells showed minimal leakage in all T cell subsets, responded to 0.1 ng/ml doxycycline, and CAR-T cells kept similar TSCM and TCM proportions with or without Dox. Protransduzin with spinoculation raised Dox-responsive T cells to as much as 67%. An anti-CD19 CAR version (iCARIs2) killed CD19+ Nalm6 and Namalwa cells only when doxycycline was present, with CD19− K562 cells unaffected. In NSG mice carrying Namal…

Download Now →

Author: María Tristán-Manzano, Noelia Maldonado-Pérez +13 more

Publications Other

Publication Date: March 13, 2023

Contact-Free, Passive, Electromagnetic Resonant Sensors for Enclosed Biomedical Applications: A Perspective on Opportunities and Challenges

Passive LC resonant sensors can monitor enclosed biological environments without contact, batteries or wires, but several obstacles still limit their use in wearable and clinical settings. They operate in the tissue-transparent radio-frequency range and respond to permittivity changes through a shift in resonant frequency. Key difficulties are environmental noise from temperature and humidity, low sensitivity to biological analytes, poor specificity because the sensing region spans centimeters, and positional misalignment between reader and sensor. Proposed remedies include differential resonator pairs, harmonic or smaller high-frequency designs, degradable transducing coatings, multi-fre…

Download Now →

Author: Adam R. Carr, Yee Jher Chan +1 more

Publications CAR T Cells G-Rex®6M Well Plate

Publication Date: March 13, 2023

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors

Human anti-EGFR CAR-T cells engineered to co-express an Akt-resistant PGC-1α (S571A) showed markedly better activity against A549 lung tumors in NSG mice than unmodified CAR-T cells, which had no effect. Unmodified CAR-T cells infiltrating tumors showed lower mitochondrial staining, more inhibitory receptors and less cytokine production than splenic cells. The PGC-1α variant raised mitochondrial mass and respiratory capacity in vitro, and RNA sequencing showed induction of mitochondrial and effector programs. Treated mice received 10^7 CAR-T cells at 100 mm³ tumors; survival was extended. Tumor-infiltrating cells made more cytokines and carried more memory markers. A truncated NT-PGC-1α r…

Download Now →

Author: Konstantinos Lontos, Yiyang Wang +11 more

Publications CAR T Cells

Publication Date: March 9, 2023

Non-viral chimeric antigen receptor (CAR) T cells going viral

Non-viral methods for producing CAR-T cells, based on transposon/transposase systems and CRISPR/Cas9 knock-in, are presented as cheaper and more flexible alternatives to viral vectors, although low knock-in efficiency remains the main obstacle. The review describes how manufacturing must change to accommodate electroporation, including larger starting and expansion volumes, new cultivation vessels, automated cell washing and enrichment platforms, and a final purification step by surface marker or drug selection. It also covers quality control for genotoxicity, from insertion-site mapping to off-target and translocation detection, prompted by lymphomas in 2 of 10 patients treated with Pigg…

Download Now →

Author: H. Balke-Want, V. Keerthi +7 more

Publications TCR T Cells G-Rex®24 Well Plate

Publication Date: March 8, 2023

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

In patients with metastatic melanoma, durable responses to anti-PD-1 therapy were associated with polyclonal CD8+ T cell responses against a small set of recurrently recognised mutations, whereas non-responders showed narrower responses. Using personalised neoantigen–HLA capture libraries, the authors isolated neoantigen-specific T cells from blood and tumour of 11 patients and cloned their T cell receptors. Responders (n = 7) had a median of 41 neoTCR clonotypes per patient versus 6.5 in non-responders (n = 4), and the mutations recognised per patient ranged from 1 to 13. Donor T cells gene-edited with these receptors using non-viral CRISPR–Cas9 killed matched melanoma cell lines; 34 of…

Download Now →

Author: Cristina Puig-Saus, Barbara Sennino +54 more

Publications NK Cells G-Rex®24 Well Plate, G-Rex®6 Well Plate

Publication Date: March 6, 2023

Ablation of SYK kinase from expanded primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production

Deleting the SYK kinase with CRISPR/Cas9 from expanded primary human NK cells increased antibody-dependent cytotoxicity, cytokine production and target-cell binding, whereas deleting ZAP-70 reduced them. The team optimized Amaxa 4D nucleofection (code CA137) of thawed donor NK cells expanded with irradiated K562-aAPC feeders, then ablated FcRγ, CD3ζ, PLZF, SYK, ZAP-70 and SHP-1 and tested the cells against antibody-coated red blood cells and SKOV-3 cells. SYK ablation raised degranulation by an average of 7% over controls, with 26 of 35 samples improving, while SHP-1 loss boosted degranulation and killing but lowered IFNγ and TNFα. SYK-ablated cells kept enhanced function for 27 days, sug…

Download Now →

Author: James D Dahlvang, Jenna K Dick +14 more

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: February 7, 2023

Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques

Anti-CD20 pre-treatment of SIV-infected rhesus macaques before CD4-MBL-CAR/CXCR5 T-cell infusion was associated with greater follicular CAR-T expansion but did not improve persistence or lower viral load. Animals on antiretroviral therapy received 7 mg/kg anti-CD20 seven days before infusion, which depleted blood CD20+ cells almost completely and lymph node CD20+ cells partially. Follicular CAR-T cells rose a median 15.2-fold between days 2 and 6 in depleted animals versus 8.1-fold in non-depleted animals, and nearly all were Ki67+. Depleted animals showed prolonged elevated IL-6, one animal developed cytokine release syndrome and was euthanized at day 2, and CAR-T cells disappeared rapidly.

Download Now →

Author: Mary S. Pampusch, Emily N. Sevcik +8 more

Publications TIL Cells G-Rex®6 Well Plate

Publication Date: February 3, 2023

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

A newly developed Syrian hamster anti-PD-L1 antibody, clone 11B12-1, controlled tumour growth in a hamster model of pancreatic ductal adenocarcinoma and made it possible to test checkpoint blockade with a replicating oncolytic adenovirus. Mice were immunized with recombinant hamster PD-L1, and hybridoma clones were screened by ELISA, flow cytometry, T-cell co-cultures, epitope binning and AlphaFold2 modelling. In HapT1 tumour-bearing hamsters, 11B12-1 gave better tumour control than isotype control by day 12 (p<0.05), whereas clone 12F1-1 did not. Combining 11B12-1 with the adenovirus TILT-123, which encodes TNFα and IL-2, improved control over the virus alone (p<0.05) by day 26, wi…

Download Now →

Author: James H. A. Clubb, Tatiana V. Kudling +25 more

Publications VST Cells G-Rex®10

Publication Date: February 2, 2023

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study

Six healthy adults who received two BNT162b2 doses showed heterogeneous antibody and T cell responses, and a simple automated assay (Jess) tracked neutralizing activity closely. Anti-spike IgG measured by Jess correlated with pseudovirus neutralization (r=0.863, P<0.0001; 24 serum samples). Spike-specific T cells were detected in 4 of 6 participants after the first dose, in all six after the second dose, and in 4 of 6 five months after vaccination. Peripheral blood mononuclear cells collected at five months were stimulated with spike peptides and grown for 11 days in a G-Rex® 10 device, giving 9 to 13.7-fold expansion in three donors and 1.8-fold in a donor with few pre-existing spike-…

Download Now →

Author: Sarra Mestiri, Maysaloun Merhi +28 more

Publications CAR T Cells, NK Cells G-Rex®6 Well Plate

Publication Date: February 2, 2023

Synapse-tuned CARs enhance immune cell anti-tumor activity

Adding a PDZ binding motif from CRTAM to the C-terminus of a CD28z CAR produces a synapse-tuned CAR that improves the function of both NK and T cells. In primary peripheral blood NK cells, the modified CAR gave stronger binding to tumor cells, higher calcium flux, smaller synaptic area and more IFNγ and perforin-secreting cells. It also improved killing in 2D and 3D assays. In three solid tumor xenograft models (A549, LM7, 143b), CAR.PDZ NK cells gave a survival advantage, and complete responders rejected tumor rechallenge about 4 months later. CAR.PDZ T cells also showed greater calcium flux and antitumor activity in glioma and osteosarcoma models.

Download Now →

Author: Peter J. Chockley, Jorge Ibanez-Vega +3 more

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: January 31, 2023

Enhancing CAR-T cell functionality in a patient-specific manner

The level of anti-CD3/anti-CD28 stimulation used to activate T cells shaped the phenotype and antitumor function of anti-CD19 CAR-T cell products, with patient-derived and healthy donor cells responding differently. T cells from eight healthy donors, six ALL patients and four CLL patients were activated with APC-mimetic scaffolds (0.02–0.3 mol%) or Dynabeads (1:1 to 5:1 bead:cell). Raising the scaffold dose from 0.1 to 0.3 mol% increased PD-1/TIM-3 co-expression and yielded progressively less cytotoxic products. In Raji lymphoma-bearing mice, 0.1 and 0.15 mol% products from one ALL patient controlled tumors similarly, whereas most animals given the 0.3 mol% product succumbed. Stimulation…

Download Now →

Author: David K. Y. Zhang, Kwasi Adu-Berchie +7 more

Publications T-Cells G-Rex®100

Publication Date: January 5, 2023

Activated T cell therapy targeting glioblastoma cancer stem cells

Autologous T cells activated with dendritic cells loaded with a pool of 18 synthetic glioblastoma-associated peptides responded more strongly than T cells activated with glioma stem cell lysate or acid-eluted peptides. HLA-A2 positive donor DCs were loaded with each antigen source and co-cultured with naïve T cells in G-Rex® 100 containers for 12 days. Lysate and eluted peptides gave no significant gain, whereas the peptide pool significantly increased IFN-γ secretion against peptide-pulsed T2 cells and four glioma stem cell lines, with CD4 and CD8 cells secreting both IFN-γ and IL-2. At a 20:1 ratio, the activated cells killed 16.1% of CSC66 stem cells versus 2% spontaneous lysis, but un…

Download Now →

Author: Ken Miyaguchi, Hongqiang Wang +4 more